What Is in TheyaVue? Ingredients Listed One by One

A xanthophyll carotenoid the body cannot make. It arrives in food, principally dark leafy greens and egg yolk, circulates on lipoproteins and is taken up selectively by the central retina, where it forms most of the macular pigment. It is first on the blend list and first on the front of the bottle.

The evidence is the strongest in this category. AREDS2 gave 10 mg a day for five years to people who already had intermediate macular degeneration. A dose-ranging trial showed serum levels rising inside two weeks and macular pigment rising at every level tested. A year-long study in healthy young adults tied the pigment change to a measurable gain in contrast sensitivity.

Twelve milligrams of lutein and zeaxanthin together is what AREDS2 used. A 240.5 mg blend could hold that with room to spare, and whether it does is a figure only the manufacturer has.

Lutein's partner. The two sit in different parts of the macula, zeaxanthin concentrated at the very centre where the cones are densest, and they are almost always studied together because separating them in a diet is close to impossible.

AREDS2 paired 2 mg of zeaxanthin with its 10 mg of lutein. The glare and photostress trial used the same pair for a year and measured how quickly vision recovers after an intense flash, which is the nearest published proxy for oncoming headlights. A separate randomised study measured visual processing speed in 69 young healthy subjects and found it improved.

It is fifth on this blend list, behind bilberry, alpha lipoic acid and eyebright, which says nothing about how much of it there is: a blend list is ordered by weight, so fifth means less than the four above it and more than the five below.

A European relative of the blueberry, used for its anthocyanins. Second on the blend list, so by weight it is behind lutein and ahead of the other eight.

It has two decent modern trials. A twelve-week trial gave 240 mg a day to 109 adults aged 20 to 60 and measured ciliary muscle tone after screen work, finding it improved at weeks eight and twelve. An eight-week trial gave 480 mg a day to office workers using display terminals and measured critical flicker fusion, a fatigue marker, finding the load-induced drop reduced.

What it does not have is the night-vision effect the folklore attaches to it. A systematic review of twelve placebo-controlled trials found the four most recent randomised ones all negative, and noted that positive results clustered in the weaker designs. The broader review of anthocyanins in people is a fair summary of where the rest of the evidence sits.

A short-chain fatty acid that works as a cofactor in mitochondrial energy production and regenerates other antioxidants. Third on the blend list.

Its largest eye trial is a negative one. A two-year randomised trial gave 600 mg a day to 467 people with type 2 diabetes and measured whether it prevented clinically significant macular oedema; 26 of 235 developed it on the drug against 30 of 232 on placebo, a difference that was not significant. Printing that is more useful than not printing it.

The positive eye record is thinner. A six-month study in thirty people used a commercial formula containing R-lipoic acid alongside taurine, vitamins C and E, lutein, zeaxanthin, zinc, copper and DHA, and measured blood antioxidant status rather than vision. It is a case-control design, not a randomised trial. The 2025 review of everything ALA has been tried on is the place to see the whole picture.

One practical note: alpha lipoic acid can lower blood glucose. Anyone on a medication that already does should know that, and the amount here is unknown because it is inside the blend.

A small European meadow plant named for the use it has been put to since the fourteenth century. Fourth on the blend list, so it is one of the larger components by weight.

The evidence is the thinnest on this label, and it is worth being exact. Its one modern randomised trial, an 84-neonate study in Bern, tested Euphrasia eye DROPS in preterm babies with ocular discharge and did not meet its primary outcome: 55.0 percent resolved on Euphrasia against 51.2 percent on saline placebo. That is a topical preparation in newborns, which has no bearing on an oral capsule in an adult.

Beyond that there is laboratory work: an in vitro study of eyebright extract against human corneal cells. Cells in a dish are where a hypothesis starts, not where it finishes. Eyebright is on this label for tradition and for its name, and this desk says so rather than dressing it up.

A flavonol, here sourced from Japanese pagoda tree buds, which are one of the richest commercial sources of it.

There is no human eye trial of quercetin to cite. What exists is mechanistic: work in retinal pigment epithelium cells and in mice found it protected the outer retinal barrier from oxidative injury by promoting autophagy. That is a reason to be interested and not a reason to expect anything.

Quercetin with a sugar attached, from the flowers of the same tree. It has a long history in vascular formulas on the argument that it supports capillary integrity.

A human supplementation study measured what happens to rutin after it is swallowed and how much antioxidant effect survives the trip. It is a bioavailability paper rather than an eye paper, and there is no eye paper to put in its place.

An amino sulfonic acid, and one of the most abundant free amino acids in the retina. That is the reason it appears on eye formulas.

A review of the retinal case for taurine sets out what is known: taurine depletion causes photoreceptor degeneration in animals, and people with mutations in the taurine transporter develop early retinal degeneration. Neither of those says that adding taurine to a well-nourished adult does anything, and no trial has shown that it does.

Taken for its proanthocyanidins, the same family of compounds bilberry is taken for.

Its best eye evidence is a twelve-month randomised trial in 124 people with non-proliferative diabetic retinopathy, given 150 mg a day against placebo and against a licensed comparator. Hard exudate severity improved more on the extract than on either. It is a real trial in a real eye condition, and the population is a long way from a healthy adult taking a general supplement.

The red carotenoid in tomatoes. Last on the blend list, so by weight it is the smallest of the ten.

Unlike lutein and zeaxanthin it is not deposited in the macula in any quantity. A serum study found lycopene lower in people with macular degeneration while lutein and zeaxanthin were not, and a population study of serum carotenoids found a broadly similar pattern. Those are associations in blood, not trials of a capsule, and the distinction matters.